Contrarian Corpus
short seller

Kerrisdale Capital

20 documents across the library, active from 2014 to 2025.

20 Documents
3.9 Avg. narrative
2.8 Avg. visual

Activity by year

14 1
17 1
18 1
19 1
20 1
21 2
22 2
23 1
24 4
25 6

All documents

Kerrisdale Capital 2025-09-01

Pure Storage, Inc. PSTG

Pure Storage's hyperscaler dream is hype: HDDs dominate at 5-6x TCO advantage, the Meta deal is replicable, and Pure deserves a peer multiple, implying ~55% downside to $35.

N4 V3 C3
Kerrisdale Capital 2025-09-01

CoreWeave, Inc. CRWV

CoreWeave is a debt-fueled, undifferentiated GPU rental stopgap with 71% Microsoft concentration and sub-WACC returns; fair value is $6–13, or 88–95% downside.

N4 V3 C3
Kerrisdale Capital 2025-08-01

Aurora Innovation, Inc. AUR

Aurora's autonomous trucking vision is a dead end: tech can only enable hub-and-spoke freight, drayage kills the economics, and the real TAM is smaller than the company's $13bn market cap.

N4 V3 C2
Kerrisdale Capital 2025-04-01

D-Wave Quantum Inc QBTS

D-Wave's quantum annealing is a commercial dead end, its 'hybrid' solvers are almost entirely classical, and at 57x 2026E revenue the stock will collapse as reality sets in.

N4 V3 C2
Kerrisdale Capital 2025-01-29

ACM Research, Inc. ACMR

ACMR trades at 1.1x revenue while its 82%-owned Shanghai subsidiary ACMS trades at 6x — a sum-of-parts gap that implies a 10-bagger as China's WFE self-sufficiency drive accelerates.

N4 V2 C2
Kerrisdale Capital 2025-01-09

Red Cat Holdings, Inc. RCAT

Red Cat's $1bn valuation rests on inflating a $23M/year Army drone contract into a $350M sole-source bonanza, with a factory that can't scale and insiders heading for the exits.

N4 V2 C2
Kerrisdale Capital 2024-11-01

Oklo Inc. OKLO

Oklo is a $3bn pre-revenue SPAC nuclear story whose 5x-lowballed fuel costs, unrealistic 2027 NRC timeline, and inexperienced 'Nuclear Bros' management mean shares should collapse as reality intrudes.

N4 V3 C2
Kerrisdale Capital 2024-08-15

Lumen Technologies LUMN

Lumen's 400% AI-fueled rally is an optical illusion: $5bn in PCF deals is construction-contractor funding worth ~$1/share, masking an insolvent, secularly declining telco with $19bn debt.

N4 V3 C2
Kerrisdale Capital 2024-06-01

Riot Platforms, Inc. RIOT

Riot Platforms is a serial-diluting bitcoin miner with $140k+ all-in cost per coin, rising Texas regulatory risk, and a broken model increasingly obviated by low-fee BTC ETFs.

N4 V3 C2
Kerrisdale Capital 2024-02-26

Carvana Co. CVNA

Carvana at $70 is priced as a tech disruptor, but it's 'just a dealership' with CarMax-like unit economics and a levered balance sheet — fair value is $16, -77%.

N4 V3 C3
Kerrisdale Capital 2023-06-15

Carvana Co. CVNA

Carvana is a poorly-run subprime used-car retailer buried under $6.5bn of debt; the recent 165% rally is a loan-sale mirage and the equity is worth zero.

N4 V3 C3
Kerrisdale Capital 2022-09-01

AST SpaceMobile, Inc. ASTS

AST SpaceMobile is a $1.8bn 2021-SPAC promoting a physically implausible direct-to-handset satellite broadband dream; the technology won't work as hyped, timelines keep slipping, and SpaceX/Apple competition eliminates any lead.

N4 V2 C2
Kerrisdale Capital 2022-04-01

Digital World Acquisition Corp DWAC

DWAC's $8bn pro-forma SPAC merger with Trump's TMTG will never close because the SEC is actively investigating it and can kill the deal via a stop order — fair value is the $10 trust cash (-80%).

N4 V2 C2
Kerrisdale Capital 2021-12-01

Astra Space, Inc. ASTR

Astra is a SPAC-bubble rocket company with no revenue, an undersized non-reusable vehicle, and fantastical 300-launch-a-year forecasts; shares should tumble back to the ground.

N4 V3 C3
Kerrisdale Capital 2021-07-01

Acutus Medical Inc. AFIB

N3 V3 C3
Kerrisdale Capital 2020-09-01

AtriCure, Inc. ATRC

AtriCure's 7.5x revenue valuation assumes stand-alone Convergent succeeds, but electrophysiologists won't refer, and PFA plus real-time mapping will obsolete surgical ablation.

N4 V3 C2
Kerrisdale Capital 2019-07-01

CareDx, Inc. CDNA

CareDx is a $1.7bn story built on AllSure, a cfDNA kidney-rejection test that misses 40% of rejections and faces 70% annual patient attrition, competition and Medicare reset — ~70% downside.

N4 V2 C2
Kerrisdale Capital 2018-04-01

The St. Joe Company JOE

St. Joe's Florida Panhandle land bank is worth a fraction of what bulls claim; absent the promised population boom, the stock is materially overvalued and a short.

N4 V3 C3
Kerrisdale Capital 2017-11-01

Adamas Pharmaceuticals, Inc. ADMS

Kerrisdale is long ADMS: Gocovri, the only FDA-approved drug for levodopa-induced dyskinesia, plus an MS and Vimpat XR pipeline, is worth over $100/share versus ~$25 today.

N4 V3 C2
Kerrisdale Capital 2014-04-07

BofI Holding BOFI

N3 V3 C3